🔗 Share this article

As the US undertakes unprecedented revisions to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on Covid vaccinations during the global health crisis and has zeroed in on possible fatalities following Covid immunization in her recent tenure at the FDA.

Proposed Changes to Childhood Immunization Program

Health officials were set to unveil sweeping changes to the childhood vaccine schedule earlier this month, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of step with much of the international standard with little proof for benefit. The planned update has been postponed until the coming year.

In place of the director of the vaccine center, Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

Consolidating Power at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood shot schedules in the US so as to align more similar to Denmark, a society with universal health coverage and a population roughly the population of the state of Wisconsin.

In her initial statements, she has kept her attention on immunizations – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in pharmaceutical research, regulation or leadership, which has been standard for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She is not an expert in industry regulation.”

Former directors of the center would “grasp laws and regulations and the science of drug development”, commented Janet Woodcock. “Objectively, she lacks the kind of background that previous people who ran the center have had.”

This division has an vast range of responsibilities at the FDA, the former commissioner stated.

“The public just pays attention on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those need to be supervised,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership component to the role, which manages more than 5,000 employees. “It is a huge management job, if you do it right,” she concluded.

Official Statement and Disputed Programs

In response to inquiries about Høeg’s credentials and whether this assignment indicates more teamwork among regulatory chiefs on vaccines, a press secretary said that the “questions rely on flawed assumptions”.

“This background aligns with the responsibilities of her role,” the official said, citing the months Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial rapid drug-approval program that allegedly concerned her former heads. “How are these therapies being selected for this voucher program? Who makes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer regulations of pharmaceuticals, aside from immunizations.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, past, Howard said. She released a analysis using unverified crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the current federal leadership featured altering rules for novel immunizations and ending “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Høeg has according to sources proposed preventing young men from getting COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her conclusions and tailors the evidence to accommodate the evidence in a highly deceptive, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other skeptics, {like|